Lisocabtagene Maraleucel in Patients With CLL or SLL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study
Lancet 2023 Jun 05;[EPub Ahead of Print], T Siddiqi, DG Maloney, SS Kenderian, DM Brander, K Dorritie, J Soumerai, PA Riedell, NN Shah, R Nath, B Fakhri, DM Stephens, S Ma, T Feldman, SR Solomon, SJ Schuster, SK Perna, SA Tuazon, SS Ou, E Papp, L Peiser, Y Chen, WG WierdaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.